Description
Tofisopam, sold under the brand names Emandaxin, Grandaxin, and Sériel, is a 2,3-benzodiazepine compound used primarily to boost the effects of other benzodiazepine sedatives. The 2,3-benzodiazepine group is unique in that they don’t work through the usual GABAergic mechanisms. This family is considered “atypical” in that they target a totally different set of receptors (AMPA). Tofisopam is indicated for the short-term management of anxiety and the relief of alcohol withdrawal syndrome. It’s being explored as a potential treatment for neurodegenerative disorders, including Alzheimer’s disease, Huntington’s disease, and amyotrophic lateral sclerosis (ALS).
Tofisopam is indicated for the treatment of anxiety and alcohol withdrawal, and is prescribed in a dosage of 50–300 mg per day divided into three doses. Peak plasma levels are attained two hours after an oral dose. Tofisopam is not reported as causing dependence to the same extent as other benzodiazepines, but is still recommended to be prescribed for a maximum of 12 weeks.
